{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":1,"description":"Participants with locally advanced or metastatic ALK-positive tumors were to receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.","id":"EG000","otherNumAffected":1,"otherNumAtRisk":1,"seriousNumAffected":1,"seriousNumAtRisk":1,"title":"ALK-positive Solid Tumors"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"medDRA 25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"Hypoaesthesia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"medDRA 25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"Aspartate aminotransferase increased"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"medDRA 25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"Headache"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"medDRA 25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"Irritability"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"medDRA 25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"Blood alkaline phosphatase increased"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"medDRA 25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"Muscular weakness"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"medDRA 25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"Weight decreased"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"medDRA 25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"Dizziness"}],"seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"medDRA 25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"Anaemia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"medDRA 25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"Myalgia"}],"timeFrame":"Approximately 1 year"}